Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 22, 2025Antimicrobial Agents and ChemotherapyOpen Access

New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJason M. PogueJHJeffrey R. HarringtonWWWalaiporn Wangchinda

Discussion

Loading...

Member takes

Overview

Commentary discusses sulbactam-durlobactam's approval by FDA for CRAB infections, suggesting carbapenem combination therapy may enhance treatment efficacy.

Key Points

  • Sulbactam-durlobactam shows potential in treating infections caused by carbapenem-resistant Acinetobacter baumannii, a critical pathogen.
  • FDA approved sulbactam-durlobactam for treating bacterial pneumonia caused by susceptible strains of A. baumannii in 2023.
  • This commentary analyzes both preclinical and clinical evidence supporting sulbactam-durlobactam's effectiveness against CRAB.
  • The findings highlight the ongoing need for innovative treatments for antimicrobial-resistant infections in healthcare settings.

Cite This Study

Pogue et al. (2025) studied this question.

synapsesocial.com/papers/68af735d7567bf4f94fecd08https://doi.org/10.1128/aac.01086-24
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1From clinical trials to daily practice: how to adequately administer sulbactam-durlobactam? alone or combined with imipenem?2025
  2. 2P40 Evaluation of sulbactam/durlobactam activity against carbapenem-resistant <i>Acinetobacter baumannii</i> in India: an institutional experience2025
  3. 3Sulbactam-durlobactam combination therapy for carbapenem-resistant Acinetobacter baumannii sepsis with cutaneous involvement in an infant with acute monocytic leukemia: A case report2025
  4. 4Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant <i>Acinetobacter baumannii</i> in Phase 1, 2, and 3 clinical trials2025
  5. 5Carbapenem-Resistant Acinetobacter baumannii: Virulence Factors, Molecular Epidemiology, and Latest Updates in Treatment Options2025 · 33 citations